Instituto Sanitas and Chemopharma have been acquired by Laboratorios Saval
March 2026 — Instituto Sanitas and Chemopharma, leading pharmaceutical laboratories in Chile, have been acquired by Laboratorios Saval S.A., a prominent pharmaceutical company based in Chile with a regional presence across Latin America. The transaction strengthens Laboratorios Saval’s growth strategy and supports its expansion in the affordable medicines segment.
Instituto Sanitas and Chemopharma are Chilean pharmaceutical laboratories with more than a century of combined experience in the development, manufacturing and commercialization of medicines for the local healthcare market. Founded in the early 20th century, the companies have built a diversified portfolio of over 150 pharmaceutical products across multiple therapeutic areas, including cardiology, neuropsychiatry, analgesics and other treatments. They serve a broad network of customers through retail pharmacies, hospitals, clinics and public health institutions across Chile, positioning themselves as long-standing suppliers within the national pharmaceutical industry.
Laboratorios Saval is a Chilean pharmaceutical company with more than 85 years of experience in the development, manufacturing and commercialization of medicines and healthcare products. Founded in the late 1930s and headquartered in Santiago, the company has established itself as a leading player in the Chilean pharmaceutical market through a diversified product portfolio, modern manufacturing facilities and long-standing relationships with healthcare professionals and institutions. The company has also developed a significant regional footprint, with operations and commercial presence across more than 14 countries in Latin America, supported by subsidiaries, distributors, and production capabilities in the region.
The sellers are part of a Chilean conglomerate with a significant presence across multiple sectors, including agriculture, pharmaceuticals and real estate.
Our role in the transaction
Oaklins’ team in Chile acted as the sole financial advisor in the transaction.
Contacter l'équipe de la transaction
Felipe Porzio
Oaklins LarrainVial
Nicole Leigh
Oaklins LarrainVial
Transactions connexes
Life & Mobility has attracted investor Bolster Investment Partners
Life & Mobility, a leading developer and manufacturer of premium mobility and rehabilitation solutions, has welcomed Bolster Investment Partners as a new shareholder. The partnership provides Life & Mobility with a strong long-term partner to support the company’s next phase of growth, with a continued focus on product innovation, strengthening its leading market position and further international expansion. The company’s mission remains to enhance the mobility, independence and quality of life of end users through innovative, sustainable and circular mobility solutions designed for multiple life cycles.
En apprendre plusAsana Gruppe has sold selected outpatient service areas to Luzerner Kantonsspital
Luzerner Kantonsspital (LUKS) has acquired key parts of Asana Spital Menziken AG’s outpatient services from Asana Gruppe AG, including its ambulance service, primary care practice and ambulatory care center. The transaction supports the long-term continuity of local medical care in the Swiss Wynen and Seetal regions and ensures these services remain available close to patients’ homes.
En apprendre plusLaboratoires Herbolistique has received a majority investment from Yotta Capital Partners and co-investors
Laboratoires Herbolistique has received a majority investment from Yotta Capital Partners alongside co-investors Ouest Croissance, Sodero and CE IDF, with Bpifrance, Océans Participations and the management team reinvesting.
En apprendre plus